Genekam to attend BIO CEO & Investor Conference
February 26-27, 2024 | New York
Genekam registered with EUDAMED - A step towards meeting the latest IVDR requirements!
Genekam is developing complex solutions based on antibody conjugates for therapeutic and diagnostic use. The antibodies can be recombinant as well as monoclonal type. Conjugates will be based on beyond the state of art technology. Some of conjugates may have potential to be used as vaccines also.